TET2 and mature T-cell and NK-cell non-Hodgkin lymphoma: Hypothetically, an additional potentially contributing factor to the occurrence of MDS and AML in the cohort of patients with PTCL treated with TEPIP might derive from potential clones with pre-lymphomatous TET2 and DNMT3A mutations.